回复 wkx323 的帖子
一直关注进展期肝癌、胆管癌和胰腺癌的系统治疗,尤其是对化疗为基础的综合治理。
我们最近1-2年内开始了进展期肝胆胰恶性肿瘤的动脉区域灌注化疗,联合免疫治疗和/或放疗。获得一定疗效和心得。
去年国际顶级医学期刊《新英格兰医学杂志》一篇文章,应该说一石掀起千层浪,即吉西他滨(健择)联合顺铂治疗胆管癌,较单一吉西他滨化学治疗疗效显著提升。
类似吉西他滨联合奥沙利铂/顺铂治疗晚期肝癌合并门静脉癌栓文献亦不少。
所以,对楼主情况,我推荐我们开展的治疗模式(先做1-2次TACE):
右腹股沟介入于腹腔动脉放置化疗导管,化疗泵放置于右腹股沟区,定期持续动脉给药化疗。我们(大致)的方案是第1周第1天吉西他滨(1000mg/m2,速度10mg/m2/min)+第2天奥沙利铂(100mg/m2,2持续小时);每2周1次。总体疗效还不错。
N Engl J Med. 2010 Apr 8;362(14):1273-81. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J; ABC-02 Trial Investigators. Collaborators (36)
Nicholson M, Corrie P, Eatock M, Falk S, Elyan S, Valle J, Anthony A, Nicoll J, Kulkarni R, Osbourne R, Garcia Alonso A, Wasan H, Waters J, Harrison M, Adamson D, Rees C, Bridgewater J, Madhusudan S, McAdam K, Bridgewater J, Maraveyas A, Palmer D, Hickish T, Meyer T, Cunningham D, Iveson T, Middleton G, Slater S, Lofts F, Archer C, Iveson T, Iveson T, Bridgewater J, Mukherjee S, Wadsley J, Gollins S.
Christie Hospital, Manchester, United Kingdom. Comment in:
AbstractBACKGROUND: There is no established standard chemotherapy for patients with locally advanced or metastatic biliary tract cancer. We initially conducted a randomized, phase 2 study involving 86 patients to compare cisplatin plus gemcitabine with gemcitabine alone. After we found an improvement in progression-free survival, the trial was extended to the phase 3 trial reported here.
METHODS: We randomly assigned 410 patients with locally advanced or metastatic cholangiocarcinoma, gallbladder cancer, or ampullary cancer to receive either cisplatin (25 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per square meter on days 1 and 8, every 3 weeks for eight cycles) or gemcitabine alone (1000 mg per square meter on days 1, 8, and 15, every 4 weeks for six cycles) for up to 24 weeks. The primary end point was overall survival.
RESULTS: After a median follow-up of 8.2 months and 327 deaths, the median overall survival was 11.7 months among the 204 patients in the cisplatin-gemcitabine group and 8.1 months among the 206 patients in the gemcitabine group (hazard ratio, 0.64; 95% confidence interval, 0.52 to 0.80; P<0.001). The median progression-free survival was 8.0 months in the cisplatin-gemcitabine group and 5.0 months in the gemcitabine-only group (P<0.001). In addition, the rate of tumor control among patients in the cisplatin-gemcitabine group was significantly increased (81.4% vs. 71.8%, P=0.049). Adverse events were similar in the two groups, with the exception of more neutropenia in the cisplatin-gemcitabine group; the number of neutropenia-associated infections was similar in the two groups.
CONCLUSIONS: As compared with gemcitabine alone, cisplatin plus gemcitabine was associated with a significant survival advantage without the addition of substantial toxicity. Cisplatin plus gemcitabine is an appropriate option for the treatment of patients with advanced biliary cancer. (ClinicalTrials.gov number, NCT00262769.)
2010 Massachusetts Medical Society
PMID: 20375404 [PubMed - indexed for MEDLINE] |